April 13th
11:00 am EDT/17:00 CEST
Scientists are increasingly using metabolomics together with other omics tools to better inform and enable critical decision-making across the various phases of the drug discovery and development process.
Experts will discuss how the integration of metabolomics with other omics data streams enables R&D programs to:
- Support target identification, mechanism of action and biomarker discovery
- Evaluate pharmacokinetics / pharmacodynamics relationships for design of optimal dosing strategy
- Understand the heterogeneity of patient populations
- Understand disease progression and drug efficacy
- Inform on potential drug repurposing
Subject Matter Experts:
- Luca A Lotta, MD, Ph.D., Vice President and Head, Cardiovascular Metabolic and Musculoskeletal Therapeutic Area Genetics, Regeneron Genetics Center (RGC), Regeneron Pharmaceuticals Inc. in New York (USA)
- Richard Beger, Ph.D., Branch Chief, Omics, Modeling, Imaging and Chemistry (OMIC) Branch, NCTR, FDA
- Rangaprasad (Ranga) Sarangarajan, Ph.D., Chief Scientific Officer, Metabolon
